| 09:00 - 09:15 | Welcome/Introductions
Dr Mark Harries/Dr Miranda Payne/Susanna Daniels |
| 09:15 - 10:00 | Stage II Melanoma: Developments as a result from advances in systemic therapies Associate Professor Alexander van Akkooi, Chair of Melanoma Surgery, Melanoma Institute of Australia |
| 09:15 – 12:30 | Pharma Exhibition Area / Posters |
| 10:10 – 10:50 | Virtual Networking:
My Melanoma: Mark Middleton |
| 11:00 – 12:00 | Pharma Sponsored Symposium: Novartis Survivorship – A new treatment goal for advanced melanoma? |
| 12:30 – 13:35 | Session 1: Molecular surveillance of melanoma
Chair: Professor Mark Middleton – Professor of Experimental Cancer Medicine in the Department of Oncology, Consultant Medical Oncologist at the Oxford Cancer and Haematology Centre |
| 12:30 – 12:55 | Circulating tumour DNA; a new tool for the clinic
Dr Rebecca Lee, Clinical Lecturer in Medical Oncology, The University of Manchester |
| 12:55 – 13:20 | Biofluid metabolomics – the other liquid biopsy for cancer detection
Dr James Larkin, Lecturer in Biochemistry, Trinity College, Oxford |
| 13:20 – 13:35 | Q&A |
| 13:35 – 14:35 | Session 2: Living beyond a stage 4 diagnosis
Chair: Lesley Howells, Maggies Lead Psychologist, Maggies Centre, Oxford |
| 13:35 – 14:15 | Caroline Kohl (10 mins), Paul Duhig (10 mins), Dr Shelley Petzer (10 mins) |
| 14:15 – 14:35 | Q&A |
| 14:35 – 14:45 | Comfort Break |
| 14:45 – 16:30 | Session 3: Practice changes in oncology Chair: Dr Ben Fairfax, Wellcome Intermediate Clinical Fellow and Honorary Consultant Medical Oncologist |
| 14:45 – 15:10 | Using Artificial Intelligence approaches to address an unmet need for melanoma
Dr Rubeta Matin, Consultant Dermatologist and Honorary Senior Clinical Lecturer, Oxford University Hospitals NHS Foundation Trust |
| 15:10 – 15:35 | Findings from the first UK Census of Skin Cancer Specialist Nurses
Dr Pippa Corrie, Consultant Medical Oncologist, Deeya Kotecha & Jashmitha Rammanohar, Final year medical students Addenbrooke’s Hospital, Cambridge |
| 15:35 – 16:15 | Melanoma immunotherapy: response and toxicity
Professor Genevieve Boland – Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School |
| 16:15 – 16:30 | Q&A |
| 16:30 – 17:25 | Session 4: MDT – Management of progression on adjuvant treatment (case-based discussions)
Chair: Dr Heather Shaw, Consultant Medical Oncologist, Mount Vernon Cancer Centre
Panel:
Mr Oliver Cassell, Consultant Plastic Surgeon, Oxford University Hospitals
Professor John Wagstaff, Professor of Medical Oncology, Swansea
Dr Steve Watkins, Consultant Oncologist, Birmingham University Hospitals
Professor Genevieve Boland, Section Head, Melanoma/Sarcoma Surgery, Surgical Director, Termeer Center for Targeted Therapies, Director, Surgical Oncology, Research Laboratories, Massachusetts General Hospital, Associate Professor of Surgery, Harvard Medical School |
| 17:25 – 17:30 | Concluding Remarks and Close
Dr Mark Harries, Chairman Melanoma Focus, Dr Miranda Payne, Organiser |
